



16/4

**MAIL STOP - AMENDMENT**  
Attorney Docket No. 26741U  
Customer No. 34375

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventor: BUHR, et al. Art Unit: 1625  
Appl. No.: 10/534,741 Examiner: Rahmani, N.  
Filing Date: May 12, 2005 Conf. No.: 9021  
Title: **8-SUBSTITUTED IMIDAZOPYRIDINES**

**TRANSMITTAL LETTER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:


1. Information Disclosure Statement
2. PTO Form-1449 with eight (8) references cited
3. Copies of the eight (8) references cited and
4. Check no. 4539 in the amount of \$180.00 for the IDS fee

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,

**THE NATH LAW GROUP**

Date: 20 July 2007

  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375

**THE NATH LAW GROUP**  
112 South West Street  
Alexandria, VA 22314  
Phone: 703-548-6284  
Fax: 703-683-8396  
GMN/SMM/le



MAIL STOP - AMENDMENT  
Attorney Docket No. 26741U  
Customer No. 34375

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: BUHR, et al. Art Unit: 1625  
Appl. No.: 10/534,741 Examiner: Rahmani, N.  
Filing Date: May 12, 2005 Conf. No.: 9021  
Title: **8-SUBSTITUTED IMIDAZOPYRIDINES**

SECOND INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

A Second Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars:  
[NOTE: One only of items a, b, c, and d must be checked.]

a. ☐ The enclosed second statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

b. ☒ The enclosed second statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed second statement is accompanied by [check one]:

☐ i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or

☒ ii. a check in the amount required by 37 C.F.R. 1.17(p).

c. ☐ The enclosed second statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

☐ Certification report(e) below; and

☐ a check in the amount as required by 1.17(p).

d. ☐ The enclosed second statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file. 07/23/2007 57EWDIE1 00000071 10534741 180.00 OP

e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed second Information Disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this second statement,

**MAIL STOP - AMENDMENT**  
Attorney Docket No. 26741U  
Customer No. 34375

- [ ] I hereby certify or that no item of information in the enclosed second Information Disclosure statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this second Information Disclosure statement.
- [ ] or Appropriate certification is attached.
- f. [XXX] If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.
- g. [XXX] Copies of the documents are attached herewith with a completed PTO Form-1449.
- [ ] or Copies of the documents are not attached, with a completed PTO Form-1449 as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:
- [ ] and / or Copies of US Patents/Publications not attached, with a completed PTO Form-1449 as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.


The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,

**THE NATH LAW GROUP**

Date: 20 July 2007

  
\_\_\_\_\_  
Gary M. Nath, Reg. No. 26,965  
Sheldon M. McGee, Reg. No. 50,454  
Customer No. 34375

**THE NATH LAW GROUP**  
112 South West Street  
Alexandria, VA 22314  
Phone: 703-548-6284  
Fax: 703-683-8396  
GMN/SMM/le



<b><u>SECOND PTO FORM-1449</u></b> <b><u>INFORMATION DISCLOSURE</u></b> <b><u>CITATION</u></b>		Inventor: BUHR, et al.		Art Unit: 1625	
		Appl. No.: 10/534,741		Examiner: Rahmani, N.	
		Filing Date: 5/12/2005		Conf. No: 9021	
<b>U.S. PATENT DOCUMENTS</b>					
Exam. Initial		Document No.	Issue/Public. Date	Inventor	Filed Date
<b>FOREIGN PATENT DOCUMENTS</b>					
Exam. Initial		Document No.	Public. Date	Country	Translation
	A7	99/55705 A1	11/4/1999	WO	N/A
	A8	99/55706 A1	11/4/1999	WO	N/A
	A9	02/060440 A1	8/8/2002	WO	N/A
	A10	02/060441 A1	8/8/2002	WO	N/A
	A11	02/060442 A1	8/8/2002	WO	N/A
<b>OTHER</b>					
Exam. Initial					
	A12	Kaminski, J.J., et al., "Antiulcer Agents. 1. Gastric Antisecretory and Cytoprotective Properties of Substituted Imidazo[1,2-a]pyridines"; <u>J. Med. Chem.</u> , Vol. 28, Pgs. 876-892, (1985).			
	A13	Kaminski, J.J., et al., "Antiulcer Agents. 6. Analysis of the in Vitro Biochemical and in Vivo Gastric Antisecretory Activity of Substituted Imidazo[1,2-a]pyridines and Related Analogues Using Comparative Molecular Field Analysis and Hypothetical Active Site Lattice Methodologies", <u>J. Med. Chem.</u> , Vol. 40, Pgs. 427-436, (1997).			

	A14	Wurst, W., et al., "Current Status of Acid Pump Antagonists (Reversible PPIs)", <u>Yale Journal of Biology and Medicine</u> , Vol. 69, Pgs. 233-243, (1996).
Examiner		Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP'609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		